Key result
Deferring compression ultrasound imaging for up to 24 hours with therapeutic doses of rivaroxaban in patients with suspected DVT resulted in a 0% rate of major bleeding incidents.
Why the study?
Guidelines recommend empiric low-molecular-weight heparin if DVT diagnostic workup is delayed, but the role of direct oral anticoagulants for deferred compression ultrasound imaging remains unexplored.
Does rivaroxaban 15 mg twice daily safely allow for deferred compression ultrasound imaging in outpatients with suspected deep vein thrombosis?
Does rivaroxaban 15 mg twice daily safely allow for deferred compression ultrasound imaging in outpatients with suspected deep vein thrombosis?
Deferring compression ultrasound imaging for up to 24 hours in patients with suspected DVT using therapeutic doses of rivaroxaban is a safe strategy with no major bleeding incidents observed.
Answers are grounded in this paper and cite their sources.
May support deferred ultrasound with rivaroxaban in suspected DVT; hypothesis-generating and requires randomized confirmation before practice change.
Guidelines suggest using empiric low-molecular-weight heparin if the diagnostic workup of deep vein thrombosis (DVT) is expected to be delayed. The role of direct oral anticoagulants for deferred compression ultrasound imaging (CUS) in patients with suspected DVT remains unexplored. The main objective of the study was to assess the safety of deferring CUS with therapeutic doses of rivaroxaban. We prospectively included consecutive outpatients referred to the Emergency Department at Østfold Hospital, Norway, with suspected first or recurrent lower-extremity DVT between February 2015 and November 2018. Patients were discharged with rivaroxaban 15 mg twice daily while awaiting CUS within 24 hours if D-dimer level was ≥0.5 mg/L fibrinogen-equivalent units. The primary outcome was the rate of major bleeding incidents from study inclusion until DVT was confirmed and anticoagulation therapy continued, or otherwise up to 48 hours following administration of the last tablet of rivaroxaban. The secondary outcome was the rate of progressive DVT symptoms or symptoms or signs of pulmonary embolism between hospital discharge until venous thromboembolism was diagnosed. Six hundred twenty-four of 1653 patients referred with suspected DVT were included (37.7%; 95% confidence interval [CI], 35.4-40.1). DVT was diagnosed in 119 patients (19.1%; 95% CI, 16.1-22.3). There were no major bleeding incidents, yielding an observed major bleeding rate of 0% (1-sided 95% CI <0.4). No patients experienced major complications in the interval that CUS was deferred (0%; 95% CI, 0.0-0.6). Deferring CUS for up to 24 hours in patients with suspected DVT with therapeutic doses of rivaroxaban is a safe strategy. This trial was registered at www.clinicaltrials.gov as #NCT02486445.
No takes yet. Share an insight, caveat, or question.
Fronas et al. (2020) studied Suspected deep vein thrombosis (n=624). Rivaroxaban was evaluated on Rate of major bleeding incidents from study inclusion until DVT was confirmed and anticoagulation therapy continued, or up to 48 hours following administration of the last tablet of rivaroxaban (95% CI <0.4). Deferring compression ultrasound imaging for up to 24 hours with therapeutic doses of rivaroxaban in patients with suspected DVT resulted in a 0% rate of major bleeding incidents.
Synapse has enriched 10 related papers. Consider them for comparative context: